Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07145866 · ClinicalTrials.gov registry record · Phase 4
Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT07145866: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT07145866 is a Phase 4 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07145866, a Phase 4 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if a combination of varenicline and accelerated Transcranial Magnetic Stimulation (aTMS) works to help adults quit using nicotine products. Researchers will compare varenicline + active aTMS to varenicline + sham (inactive) aTMS to see the effect of aTMS on reaching abstinence. The main question it aims to answer is: Does receiving active aTMS + varenicline lead to higher abstinence rates and lower nicotine craving? Participants will be asked to: * Complete 2 brain MRI scans * Take varenicline every day for 12 weeks * Quit using nicotine products at the end of the second week of varenicline * Complete 5 consecutive days (Monday-Friday, uninterrupted) of TMS treatments * Complete 12 brief, weekly follow-up visits * Complete a brief daily survey each day that they take the study drug
Interventions
- DEVICE Transcranial Magnetic Stimulation
- DEVICE Transcranial Magnetic Stimulation Sham
- DRUG varenicline
- BEHAVIORAL Nicotine Cessation Counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-15 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07145866
The ClinicalTrials.gov registry entry for NCT07145866 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Transcranial Magnetic Stimulation is the first listed.
NCT07145866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07145866 about?
NCT07145866 is a clinical study titled "Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)". The goal of this clinical trial is to learn if a combination of varenicline and accelerated Transcranial Magnetic Stimulation (aTMS) works to help adults quit using nicotine products. Researchers will compare varenicline + active aTMS to varenicline + sham (inactive) aTMS to see the effect of aTMS o...
What is the current status of trial NCT07145866?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2026-03-15. Estimated completion is 2027-12-01.
What interventions are being tested in trial NCT07145866?
The interventions under investigation include: Transcranial Magnetic Stimulation (DEVICE), Transcranial Magnetic Stimulation Sham (DEVICE), varenicline (DRUG), Nicotine Cessation Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT07145866?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.